Skip to Content

Clinical Trials Detail

BRF113928: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations

Objective
This is a clinical trial of GSK2118436 that will be administered by mouth which is investigational.
IRB Protocol Number
11-1537
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • Lung Cancer
Sponsor(s)
GlaxoSmithKline
Contact
AMY BROWN at 720-848-0603
or AMY.M.BROWN@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 2 years. A follow up period will consist of phone contact and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.